113 related articles for article (PubMed ID: 15319247)
1. The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma.
Andreopoulou E; Ross PJ; O'Brien ME; Ford HE; Priest K; Eisen T; Norton A; Ashley S; Smith IE
Ann Oncol; 2004 Sep; 15(9):1406-12. PubMed ID: 15319247
[TBL] [Abstract][Full Text] [Related]
2. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
Middleton GW; Smith IE; O'Brien ME; Norton A; Hickish T; Priest K; Spencer L; Ashley S
Ann Oncol; 1998 Mar; 9(3):269-73. PubMed ID: 9602260
[TBL] [Abstract][Full Text] [Related]
3. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
6. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
7. Treatment of malignant mesothelioma with methotrexate and vinblastine, with or without platinum chemotherapy.
Hunt KJ; Longton G; Williams MA; Livingston RB
Chest; 1996 May; 109(5):1239-42. PubMed ID: 8625674
[TBL] [Abstract][Full Text] [Related]
8. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
O'Brien ME; Watkins D; Ryan C; Priest K; Corbishley C; Norton A; Ashley S; Rowell N; Sayer R
Ann Oncol; 2006 Feb; 17(2):270-5. PubMed ID: 16317014
[TBL] [Abstract][Full Text] [Related]
9. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
10. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
Muers MF; Stephens RJ; Fisher P; Darlison L; Higgs CM; Lowry E; Nicholson AG; O'Brien M; Peake M; Rudd R; Snee M; Steele J; Girling DJ; Nankivell M; Pugh C; Parmar MK;
Lancet; 2008 May; 371(9625):1685-94. PubMed ID: 18486741
[TBL] [Abstract][Full Text] [Related]
11. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
[TBL] [Abstract][Full Text] [Related]
12. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.
Pennucci MC; Ardizzoni A; Pronzato P; Fioretti M; Lanfranco C; Verna A; Giorgi G; Vigani A; Frola C; Rosso R
Cancer; 1997 May; 79(10):1897-902. PubMed ID: 9149015
[TBL] [Abstract][Full Text] [Related]
13. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
14. BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112.
Muers MF; Rudd RM; O'Brien ME; Qian W; Hodson A; Parmar MK; Girling DJ;
Thorax; 2004 Feb; 59(2):144-8. PubMed ID: 14760156
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
J Clin Oncol; 1994 Jun; 12(6):1156-63. PubMed ID: 8201377
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
Metintas M; Ozdemir N; Uçgun I; Elbek O; Kolsuz M; Mutlu S; Metintas S
Chest; 1999 Aug; 116(2):391-8. PubMed ID: 10453867
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
Tsavaris N; Mylonakis N; Karvounis N; Bacoyiannis C; Briasoulis E; Skarlos D; Pavlidis N; Stamatelos G; Kosmidis P
Lung Cancer; 1994 Sep; 11(3-4):299-303. PubMed ID: 7812707
[TBL] [Abstract][Full Text] [Related]
18. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
[TBL] [Abstract][Full Text] [Related]
19. Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer.
Ferrigno D; Buccheri G
Acta Oncol; 1996; 35(4):435-9. PubMed ID: 8695157
[TBL] [Abstract][Full Text] [Related]
20. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
